Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial

BACKGROUND: Optimal drug treatment for patients with resistant hypertension is undefined. We aimed to test the hypotheses that resistant hypertension is most often caused by excessive sodium retention, and that spironolactone would therefore be superior to non-diuretic add-on drugs at lowering blood...

Descripción completa

Detalles Bibliográficos
Autores principales: Williams, Bryan, MacDonald, Thomas M, Morant, Steve, Webb, David J, Sever, Peter, McInnes, Gordon, Ford, Ian, Cruickshank, J Kennedy, Caulfield, Mark J, Salsbury, Jackie, Mackenzie, Isla, Padmanabhan, Sandosh, Brown, Morris J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4655321/
https://www.ncbi.nlm.nih.gov/pubmed/26414968
http://dx.doi.org/10.1016/S0140-6736(15)00257-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4655321/
https://www.ncbi.nlm.nih.gov/pubmed/26414968
http://dx.doi.org/10.1016/S0140-6736(15)00257-3

Ejemplares similares